NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer

NOX-A12 in Second Oncology Indication: Multiple Myeloma

28-Sep-2012 - Germany

NOXXON Pharma announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer® NOX-A12. CXCL12 signaling has been shown to play an important role in the pathophysiology of MM, especially in the interaction of MM cells with the bone marrow microenvironment. By inhibiting this interaction NOX-A12 sensitizes the cancer cells to chemotherapy.

This is the third Phase IIa trial that NOXXON has started this year following the NOX-E36 Phase IIa for the treatment of diabetic nephropathy in June and the NOX-A12 Phase IIa for the treatment of Chronic Lymphocytic Leukemia in July.

MM is a hematologic or blood cancer that develops in the bone marrow in which normal antibody-pro­ducing cells transform into malignant myeloma. The growth of the cancer cells in the bone marrow blocks production of normal blood cells and antibodies, and also causes lesions that weaken the bone. According to the US National Cancer Institute (NCI), MM is the second most common blood cancer in the United States and accounts for approximately one percent of all cancers.

NOXXON's multi-center, open-label, uncontrolled study will be conducted in Europe on 28 relapsed MM patients who were all previously treated for their cancer. The patients will receive NOX-A12 in combination with a background therapy of Velcade®/bortezomib and dexamethasone (VD). Combina­tion treatment with NOX-A12 and VD will occur in 8 cycles of 21 days, with a follow-up period of one year. Each patient will receive up to three different doses of NOX-A12 as part of an individualized dose titration. The primary efficacy endpoint of the study will be the overall response rate, which includes patients with complete and partial responses to therapy. NOXXON expects interim results to be avail­able by the end of 2012.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...